RLMD logo

RLMD
Relmada Therapeutics Inc

2,115
Mkt Cap
$788.76M
Volume
38.00
52W High
$7.94
52W Low
$0.3233
PE Ratio
-5.12
RLMD Fundamentals
Price
$7.52
Prev Close
$7.37
Open
$7.40
50D MA
$6.26
Beta
0.53
Avg. Volume
3.21M
EPS (Annual)
-$1.45
P/B
6.37
Rev/Employee
$0.00
$97.68
Loading...
Loading...
News
all
press releases
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3% - Here's What Happened
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 4.3% - What's Next...
MarketBeat·15d ago
News Placeholder
More News
News Placeholder
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 6,042,204 shares, an increase of 61.9% from the March 15th total of 3,731,201 shares. Currently, 7.3% of the company's stock...
MarketBeat·18d ago
News Placeholder
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·18d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Hits New 12-Month High - Should You Buy?
Relmada Therapeutics (NASDAQ:RLMD) Sets New 12-Month High - Here's What Happened...
MarketBeat·22d ago
News Placeholder
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Small drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments.
Zacks·25d ago
News Placeholder
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Zacks·29d ago
News Placeholder
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·1mo ago
News Placeholder
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) was the target of a large increase in short interest in March. As of March 13th, there was short interest totaling 3,731,201 shares, an...
MarketBeat·1mo ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Earns Overweight Rating from Analysts at Piper Sandler
Piper Sandler started coverage on Relmada Therapeutics in a research note on Tuesday. They set an "overweight" rating and a $12.00 price objective for the company...
MarketBeat·1mo ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) Price Target Raised to $19.00
Mizuho raised their target price on Relmada Therapeutics from $10.00 to $19.00 and gave the stock an "outperform" rating in a research note on Friday...
MarketBeat·1mo ago
<
1
2
...
>

Latest RLMD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.